Browse Full Report: https://www.precisemarketintelligence.com/report/9/intravenous-immunoglobulin-market
Immunoglobulin therapy, also known as normal human immunoglobulin (NHIG), is the use of a mixture of antibodies (immunoglobulins) to treat a number of health conditions. These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barré syndrome, and certain other infections when a more specific immunoglobulin is not available. Based on formulation, it can be administered intravenously of subcutaneously.
The global Intravenous Immunoglobulin (IVIg) market size was estimated to be at USD XXX million in 2019, and is expected to grow at a CAGR of XX% during forecast period to reach USD XXX million in 2027.
Market Dynamics:
There is an increasing demand for the intravenous immunoglobulin which can be attributed to the increasing awareness of the patient regarding the various forms of immunodeficiencies. Intravenous immunoglobulins are increasingly and widely recognized as the treatment for a number of medical conditions primarily. The ability of intravenous immunoglobulin in efficient treatment of patients with immunodeficiencies, combined with advent of new diagnostic procedures for the determination of the form of immunodeficiency is further expected to boost the market growth. But a disadvantage is encountered when one considers the cost of the immunoglobulin therapy, in regions where there are not adequate reimbursements for immunoglobulin and at the same instance, the patient is not prepared to undertake the significant burden of the cost of intravenous immunoglobulins. The early detection of primary immunodeficiency is ideal and optimum for the most effective treatment but in many of the emerging markets presents the huge opportunity for market players.
